ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

DCBDC Board Cool to Proposals On Study Sections

November 23, 1990

In Brief: LYNNE PENBERTHY Was Named Associate Director For Surveillance Research In NCI’s Division of Cancer Control and Population Sciences

November 8, 2013

Oxandrolone And Education Improves Weight Gain

February 28, 2003

Breast Cancer Task Force Must Take More Active Role In RFP Development, New Chairman Insists

November 14, 1975

FDA Approves Ribavirin Phase 102 Trials

October 30, 1987

Stop Cancer Promises $7 Mil. By End Of Year

October 12, 1990